Citius Pharmaceuticals Stock Price

-0.01 (-0.93%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Citius Pharmaceuticals Inc CTXR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.01 -0.93% 1.07 00:00:03
Close Price Low Price High Price Open Price Previous Close
1.07 1.04 1.09 1.05 1.08
Bid Price Ask Price Spread News
1.03 1.10 0.07 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
878 581,280 $ 1.06 $ 616,111 4,995,886 0.40 - 1.97
Last Trade Time Type Quantity Stock Price Currency
19:41:30 formt 1,000 $ 1.07 USD

Citius Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 48.35M 45.19M 32.90M $ - $ - -0.78 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 27.20%

more financials information »

Citius Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CTXR Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.,722,742-0.04-3.6%
1 Month1.361.771.001.292,149,104-0.29-21.32%
3 Months1.031.970.8011.253,435,5750.043.88%
6 Months0.991.970.4151.132,125,1960.088.08%
1 Year1.081.970.401.101,234,175-0.01-0.93%
3 Years2.915.490.401.23493,521-1.84-63.23%
5 Years3.405.490.401.23489,752-2.33-68.53%

Citius Pharmaceuticals Description

Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. It is primarily operating within the critical care and cancer care market segments.

Your Recent History
Citius Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.